HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY2584702

Also Known As:

4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)-1-piperidinyl)-1H-pyrazolo(3,4-d)pyrimidine; LY 2584702; LY-2584702; LY2584702 tosylate

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - LY2584702: 4
  - Pyrimidines: 510
    - LY2584702: 4

Experts

1.	Leohr, Jennifer K: 2 articles (01/2018 - 01/2017)
2.	Luffer-Atlas, Debra: 2 articles (01/2018 - 01/2017)
3.	Luo, M Jane: 2 articles (01/2018 - 01/2017)
4.	Mabry, Thomas E: 2 articles (01/2018 - 01/2017)
5.	Bonifaci, Núria: 1 article (01/2022)
6.	Dien Nguyen, Van: 1 article (01/2022)
7.	Fernández-Real, José M: 1 article (01/2022)
8.	Höring, Marcus: 1 article (01/2022)
9.	Kozma, Sara C: 1 article (01/2022)
10.	Latorre, Jèssica: 1 article (01/2022)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 01/01/2018 - "Although clinical investigation of LY2584702 has been terminated because of hepatotoxicity risk, we suggest that a selective inhibitor of p70 S6 serine/threonine protein kinase-1 with a larger margin of safety and without the possibility of being metabolized to 4-APP may be useful in the treatment of dyslipidemia."
2.	Neoplasms (Cancer) 01/01/2022 - "Here, we assess the therapeutic blockage of S6K1 in diet-induced obese mice challenged with LY2584702 tosylate, a specific oral S6K1 inhibitor initially developed for the treatment of solid tumors. " 01/01/2017 - "LY2584702 is an inhibitor of p70 S6 kinase-1 previously developed for the treatment of cancer. "
3.	Hepatocellular Carcinoma (Hepatoma) 01/01/2017 - "In human hepatoma HepG2 cells, 4-APP, but not LY2584702, increased LDL uptake. "
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/01/2017 - "To illustrate the underlying mechanism of RPS6KB1 phosphorylation in NSCLC, LY2584702 was employed to inhibit the RPS6KB1 phosphorylation specifically both in lung adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1. "
5.	Adenocarcinoma of Lung 01/01/2017 - "To illustrate the underlying mechanism of RPS6KB1 phosphorylation in NSCLC, LY2584702 was employed to inhibit the RPS6KB1 phosphorylation specifically both in lung adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1. "

Related Drugs and Biologics

1.	4-azidophenylpropionamide
2.	Threonine (L-Threonine)
3.	Serine (L-Serine)
4.	Proteins (Proteins, Gene)
5.	oxidized low density lipoprotein